Protective effect of Shenxiang Suhe Pill on myocardial ischemia-reperfusion injury and the related mechanism

Phase 4

Conditions: Coronary atherosclerotic heart disease

Registration Number: ITMCTR2200005484

Lead Sponsor: Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

1. Age = 18 years;
2. Both groups of patients with MI were patients with acute anterior ST segment elevation myocardial infarction in our hospital. PCI treatment was completed within 12 hours after onset. It was necessary to meet the angiographic diagnosis of total closure of the proximal anterior descending branch, TIMI blood flow grade 0-1, and the proximal anterior descending branch was defined as the end of the left main trunk to the origin of the first diagonal branch;
3. The two groups of patients with SPCI were patients with a single proximal anterior descending artery lesion who underwent elective PCI. The proximal segment of the anterior descending artery was defined as the origin from the end of the left main artery to the first diagonal artery. The lesion of the proximal segment of the single anterior descending artery was defined as stenosis = 70% and the degree of stenosis of other coronary artery = 50%;
4. The anterior descending artery lesions were successfully opened in all patients. The success criteria were: residual stenosis < 20%, no tear, thrombosis or embolic signs of distal vessels;
5. The patient gave informed consent and signed the informed consent form. Be able to participate in outpatient follow-up.

Exclusion Criteria

1. In myocardial infarction group, angiography showed recanalization of anterior descending artery and TIMI blood flow grade 3;
2. Received thrombolytic therapy before PCI;
3. No previous history of cardiac insufficiency caused by any reason;
4. No previous history of structural heart disease, including valvular heart disease, congenital heart disease, pulmonary heart disease, cardiomyopathy, etc;
5. No previous myocardial infarction;
6. Psychiatric patients;
7. Have participated in other clinical trials (just completed or still in progress in recent 2 months);
8. Pregnant or lactating women or women planning pregnancy;
9. The researcher judged that the compliance of the patient was not good and could not strictly implement the scheme;
10. Any other circumstances that the investigator considers unsuitable for participation in the trial.

Study & Design

Study Type: Interventional study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Perfusion defect area;Perfusion defect score;

Secondary Outcome Measures

Name	Time	Method
Whole blood viscosity;Left ventricular ejection fraction;NOS;Status of arrhythmia;New York Heart Association classification of cardiac function;NT-proBNP;NO;Mace includes cardiac death, nonfatal reinfarction and new onset heart failure;Cu/Zn-SOD;Left ventricular end diastolic diameter;Mn-SOD;TNF-a;IL-6;MDA;